Physician profile
Bernard Moye
NPI 1386675635
$2,021.52
in general payments reported to CMS, 2019-2025
22 companies · $30.14 in 2025
The $30.14 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $661 · 2022: $791 · 2023: $338 · 2024: $201 · 2025: $30.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $568.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $518.38 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $468.76 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $209.29 | 2021-2024 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $198.41 | 2022-2023 | Trelegy Ellipta |
| Abbvie INC. | $102.32 | 2021-2024 | |
| Horizon Therapeutics Plc | $60.86 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.39 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.58 | 2021-2023 | Xifaxan |
| Phadia US INC. | $45.65 | 2021-2024 | Immunocap |
| Amarin Pharma, INC. | $45.23 | 2021 | |
| Exact Sciences Corporation | $44.49 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $31.40 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $30.46 | 2022-2023 | Rexulti |
| Eisai INC. | $27.26 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $18.04 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $17.08 | 2024 | |
| Azurity Pharmaceuticals, INC. | $16.37 | 2024 | Horizant |
| Novartis Pharmaceuticals Corporation | $15.90 | 2021 | |
| Lifescan, INC. | $14.11 | 2022 | |
| Smith+Nephew, INC. | $13.66 | 2021 | |
| Nestle Healthcare Nutrition INC. | $13.03 | 2021 | |
| Endo Pharmaceuticals INC. | $11.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Moye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.